Growth differentiation factor 11 is a protective factor for osteoblastogenesis by targeting PPARgamma

Gene

Volumn 557, Issue 2, 2015, Pages 209-214

  Zhang, Yan ^a   Shao, Jin ^a   Wang, Zhi ^a   Yang, Tieyi ^a   Liu, Shuyi ^a   Liu, Yue ^a   Fan, Xinbing ^a   Ye, Weiguang ^a  

^a Gongli Hospital Pudong New Area   (China)

Author keywords

GDF11; Osteoblastogenesis; Osteoporosis; PPAR

Indexed keywords

GROWTH DIFFERENTIATION FACTOR; GROWTH DIFFERENTIATION FACTOR 11; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UNCLASSIFIED DRUG; BONE MORPHOGENETIC PROTEIN; GDF11 PROTEIN, HUMAN;

ADIPOCYTE; ADIPOGENESIS; ADULT; AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; HOMEOSTASIS; HUMAN; MOUSE; NONHUMAN; OSTEOBLASTOGENESIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN TARGETING; SUMOYLATION; ANIMAL; C57BL MOUSE; GENE EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; OSTEOBLAST; PHYSIOLOGY;

MUS;

ADIPOGENESIS; ANIMALS; BONE MORPHOGENETIC PROTEINS; FEMALE; GENE EXPRESSION; GROWTH DIFFERENTIATION FACTORS; HUMANS; MICE, INBRED C57BL; MIDDLE AGED; OSTEOBLASTS; OSTEOPOROSIS; PPAR GAMMA; SUMOYLATION;

EID: 84920945268     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2014.12.039     Document Type: Article

References (30)

1. Akune T., Ohba S., Kamekura S., Yamaguchi M., Chung U.I., Kubota N., Terauchi Y., Harada Y., Azuma Y., Nakamura K., Kadowaki T., Kawaguchi H. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J. Clin. Invest. 2004, 113:846-855.
2. Biesemann N., Mendler L., Wietelmann A., Hermann S., Schäfers M., Krüger M., Boettger T., Borchardt T., Braun T. Myostatin regulates energy homeostasis in the heart and prevents heart failure. Circ. Res. 2014, 115:296-310.
3. Canalis E., Giustina A., Bilezikian J.P. Mechanisms of anabolic therapies for osteoporosis. N. Engl. J. Med. 2007, 357:905-916.
4. Chang J., Wang Z., Tang E., Fan Z., McCauley L., Franceschi R., Guan K., Krebsbach P.H., Wang C.Y. Inhibition of osteoblastic bone formation by nuclear factor-kappaB. Nat. Med. 2009, 15:682-689.
5. Dutchak P.A., Katafuchi T., Bookout A.L., Choi J.H., Yu R.T., Mangelsdorf D.J., Kliewer S.A. Fibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinediones. Cell 2012, 148:556-567.
6. Gates B.J., Das S. Management of osteoporosis in elderly men. Maturitas 2011, 69:113-119.
7. Harslof T., Tofteng C.L., Husted L.B., Nyegaard M., Borglum A., Carstens M., Stenkjaer L., Brixen K., Eiken P., Jensen J.E., Mosekilde L., Rejnmark L., Langdahl B.L. Polymorphisms of the peroxisome proliferator-activated receptor gamma (PPARgamma) gene are associated with osteoporosis. Osteoporos. Int. 2011, 22:2655-2666.
8. Kang S., Bennett C.N., Gerin I., Rapp L.A., Hankenson K.D., Macdougald O.A. Wnt signaling stimulates osteoblastogenesis of mesenchymal precursors by suppressing CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 2007, 282:14515-14524.
9. Karsenty G., Kronenberg H.M., Settembre C. Genetic control of bone formation. Annu. Rev. Cell Dev. Biol. 2009, 25:629-648.
10. Katsimpardi L., Litterman N.K., Schein P.A., Miller C.M., Loffredo F.S., Wojtkiewicz G.R., Chen J.W., Lee R.T., Wagers A.J., Rubin L.L. Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. Science 2014, 344:630-634.
11. Kawai M., Rosen C.J. PPARgamma: a circadian transcription factor in adipogenesis and osteogenesis. Nat. Rev. Endocrinol. 2010, 6:629-636.
12. Kim J.K., Noh J.H., Jung K.H., Eun J.W., Bae H.J., Kim M.G., Chang Y.G., Shen Q., Park W.S., Lee J.Y., Borlak J., Nam S.W. Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b. Hepatology 2013, 57:1055-1067.
13. Krum S.A., Miranda-Carboni G.A., Hauschka P.V., Carroll J.S., Lane T.F., Freedman L.P., Brown M. Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J. 2008, 27:535-545.
14. Lazarenko O.P., Rzonca S.O., Hogue W.R., Swain F.L., Suva L.J., Lecka-Czernik B. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 2007, 148:2669-2680.
15. Loffredo F.S., Steinhauser M.L., Jay S.M., Gannon J., Pancoast J.R., Yalamanchi P., Sinha M., Dall'Osso C., Khong D., Shadrach J.L., Miller C.M., Singer B.S., Stewart A., Psychogios N., Gerszten R.E., Hartigan A.J., Kim M.J., Serwold T., Wagers A.J., Lee R.T. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell 2013, 153:828-839.
16. Lu L., Li L., Lv X., Wu X.-S., Liu D.-P., Liang C.-C. Modulations of hMOF autoacetylation by SIRT1 regulate hMOF recruitment and activities on the chromatin. Cell Res. 2011, 21:1182-1195.
17. McPherron A.C., Lawler A.M., Lee S.J. Regulation of anterior/posterior patterning of the axial skeleton by growth/differentiation factor 11. Nat. Genet. 1999, 22:260-264.
18. Novack D.V., Teitelbaum S.L. The osteoclast: friend or foe?. Annu. Rev. Pathol. 2008, 3:457-484.
19. Rachner T.D., Khosla S., Hofbauer L.C. Osteoporosis: now and the future. Lancet 2011, 377:1276-1287.
20. Shi Y., Liu J.P. Gdf11 facilitates temporal progression of neurogenesis in the developing spinal cord. J. Neurosci. 2011, 31:883-893.
21. Sinha M., Jang Y.C., Oh J., Khong D., Wu E.Y., Manohar R., Miller C., Regalado S.G., Loffredo F.S., Pancoast J.R., Hirshman M.F., Lebowitz J., Shadrach J.L., Cerletti M., Kim M.J., Serwold T., Goodyear L.J., Rosner B., Lee R.T., Wagers A.J. Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. Science 2014, 344:649-652.
22. Takada I., Mihara M., Suzawa M., Ohtake F., Kobayashi S., Igarashi M., Youn M.Y., Takeyama K., Nakamura T., Mezaki Y., Takezawa S., Yogiashi Y., Kitagawa H., Yamada G., Takada S., Minami Y., Shibuya H., Matsumoto K., Kato S. A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-gamma transactivation. Nat. Cell Biol. 2007, 9:1273-1285.
23. Tanishima S., Morio Y. A review of minodronic acid hydrate for the treatment of osteoporosis. Clin. Interv. Aging 2013, 8:185-189.
24. Wan Y. PPARgamma in bone homeostasis. Trends Endocrinol. Metab. 2010, 21:722-728.
25. Wan Y., Chong L.W., Evans R.M. PPAR-gamma regulates osteoclastogenesis in mice. Nat. Med. 2007, 13:1496-1503.
26. Wei W., Wang X., Yang M., Smith L.C., Dechow P.C., Sonoda J., Evans R.M., Wan Y. PGC1beta mediates PPARgamma activation of osteoclastogenesis and rosiglitazone-induced bone loss. Cell Metab. 2010, 11:503-516.
27. Wei W., Zeve D., Suh J.M., Wang X., Du Y., Zerwekh J.E., Dechow P.C., Graff J.M., Wan Y. Biphasic and dosage-dependent regulation of osteoclastogenesis by beta-catenin. Mol. Cell. Biol. 2011, 31:4706-4719.
28. Wei W., Zeve D., Wang X., Du Y., Tang W., Dechow P.C., Graff J.M., Wan Y. Osteoclast progenitors reside in the peroxisome proliferator-activated receptor gamma-expressing bone marrow cell population. Mol. Cell. Biol. 2011, 31:4692-4705.
29. Wei W., Dutchak P.A., Wang X., Ding X., Wang X., Bookout A.L., Goetz R., Mohammadi M., Gerard R.D., Dechow P.C., Mangelsdorf D.J., Kliewer S.A., Wan Y. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor gamma. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:3143-3148.
30. Zaidi M. Skeletal remodeling in health and disease. Nat. Med. 2007, 13:791-801.